CalciMedica Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • CALC

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.75
  • (As of Monday Closing)

CalciMedica General Information

Description

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

Contact Information

Formerly Known As
GRAYBUG LLC, GRAYBUG VISION, INC., GRAYBUG, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 505 Coast Boulevard South
  • Suite 307, La Jolla
  • San Diego, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 505 Coast Boulevard South
  • Suite 307, La Jolla
  • San Diego, CA 92037
  • United States
+1 (858)

CalciMedica Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CalciMedica Stock Performance

As of 10-Feb-2025, CalciMedica’s stock price is $2.75. Its current market cap is $37.1M with 13.5M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.75 $2.67 $2.05 - $6.26 $37.1M 13.5M 46.1K -$1.11

CalciMedica Financials Summary

As of 30-Sep-2024, CalciMedica has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 28,486 1,668 (32,544) (33,539)
Revenue 0 0 0 0
EBITDA (13,525) (34,189) (7,640) (35,428)
Net Income (13,588) (34,357) (7,824) (35,821)
Total Assets 16,212 12,185 3,349 69,088
Total Debt 0 0 5,157 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CalciMedica Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CalciMedica‘s full profile, request access.

Request a free trial

CalciMedica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore CalciMedica‘s full profile, request access.

Request a free trial

CalciMedica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infla
Drug Discovery
San Diego, CA
13 As of 2024

Cambridge, MA

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CalciMedica Competitors (49)

One of CalciMedica’s 49 competitors is AnTolRx, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA
Parion Sciences Venture Capital-Backed Durham, NC
NexImmune Formerly VC-backed Gaithersburg, MD
Topas Therapeutics Venture Capital-Backed Hamburg, Germany
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
You’re viewing 5 of 49 competitors. Get the full list »

CalciMedica Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CalciMedica Acquisitions (1)

CalciMedica’s most recent deal was a Merger/Acquisition with Graybug Vision. The deal was made on 20-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Graybug Vision 20-Mar-2023 Merger/Acquisition Drug Delivery
To view CalciMedica’s complete acquisitions history, request access »

CalciMedica ESG

Risk Overview

Risk Rating

Updated June, 08, 2021

39.86 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,042

Rank

Percentile

Pharmaceuticals

Industry

of 947

Rank

Percentile

Biotechnology

Subindustry

of 452

Rank

Percentile

To view CalciMedica’s complete esg history, request access »

CalciMedica FAQs

  • When was CalciMedica founded?

    CalciMedica was founded in 2006.

  • Where is CalciMedica headquartered?

    CalciMedica is headquartered in San Diego, CA.

  • What is the size of CalciMedica?

    CalciMedica has 13 total employees.

  • What industry is CalciMedica in?

    CalciMedica’s primary industry is Drug Discovery.

  • Is CalciMedica a private or public company?

    CalciMedica is a Public company.

  • What is CalciMedica’s stock symbol?

    The ticker symbol for CalciMedica is CALC.

  • What is the current stock price of CalciMedica?

    As of 10-Feb-2025 the stock price of CalciMedica is $2.75.

  • What is the current market cap of CalciMedica?

    The current market capitalization of CalciMedica is $37.1M.

  • Who are CalciMedica’s competitors?

    AnTolRx, Parion Sciences, NexImmune, Topas Therapeutics, and Cristal Therapeutics are some of the 49 competitors of CalciMedica.

  • What is CalciMedica’s annual earnings per share (EPS)?

    CalciMedica’s EPS for 12 months was -$1.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »